DE60324296D1 - Kondensierte azolpyrimidinderivate - Google Patents

Kondensierte azolpyrimidinderivate

Info

Publication number
DE60324296D1
DE60324296D1 DE60324296T DE60324296T DE60324296D1 DE 60324296 D1 DE60324296 D1 DE 60324296D1 DE 60324296 T DE60324296 T DE 60324296T DE 60324296 T DE60324296 T DE 60324296T DE 60324296 D1 DE60324296 D1 DE 60324296D1
Authority
DE
Germany
Prior art keywords
azolpyrimidine
condensed
derivatives
condensed azolpyrimidine
azolpyrimidine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324296T
Other languages
English (en)
Inventor
Mitsuyuki Shimada
Toshiki Murata
Kinji Fuchikami
Hideki Tsujishita
Naoki Omori
Issei Kato
Mami Miura
Klaus Urbahns
Florian Gantner
Kevin Bacon
Jolla La
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Application granted granted Critical
Publication of DE60324296D1 publication Critical patent/DE60324296D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60324296T 2002-09-30 2003-09-18 Kondensierte azolpyrimidinderivate Expired - Lifetime DE60324296D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021861 2002-09-30
PCT/EP2003/010377 WO2004029055A1 (en) 2002-09-30 2003-09-18 Fused azole-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
DE60324296D1 true DE60324296D1 (de) 2008-12-04

Family

ID=32039115

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324296T Expired - Lifetime DE60324296D1 (de) 2002-09-30 2003-09-18 Kondensierte azolpyrimidinderivate

Country Status (33)

Country Link
US (2) US7511041B2 (de)
EP (2) EP2042504B1 (de)
JP (1) JP4790266B2 (de)
KR (1) KR101059652B1 (de)
CN (1) CN100384846C (de)
AR (2) AR041426A1 (de)
AT (2) ATE411996T1 (de)
AU (1) AU2003293310B2 (de)
BR (1) BRPI0314830B8 (de)
CA (1) CA2499134C (de)
CY (2) CY1109790T1 (de)
DE (1) DE60324296D1 (de)
DK (2) DK1549652T3 (de)
EC (2) ECSP055768A (de)
ES (2) ES2367141T3 (de)
HK (1) HK1084393A1 (de)
HR (2) HRP20050375B1 (de)
IL (1) IL166855A (de)
MA (1) MA27483A1 (de)
MX (1) MXPA05001808A (de)
MY (1) MY140756A (de)
NO (1) NO331457B1 (de)
NZ (1) NZ539062A (de)
PE (1) PE20050089A1 (de)
PL (1) PL226562B1 (de)
PT (2) PT1549652E (de)
RU (1) RU2326881C9 (de)
SI (2) SI2042504T1 (de)
TW (1) TWI327570B (de)
UA (1) UA82205C2 (de)
UY (1) UY28001A1 (de)
WO (1) WO2004029055A1 (de)
ZA (1) ZA200503306B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005021488A1 (ja) 2003-08-29 2005-03-10 Mitsui Chemicals, Inc. 農園芸用殺虫剤及びその使用方法
PT1761540T (pt) 2004-05-13 2016-12-07 Icos Corp Quinazolinonas como inibidores de fosfatidilinositol-3-cinase delta humana
WO2006040279A1 (de) 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh Pi3-kinasen
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
EP2360279A1 (de) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnose für Lungenerkrankungen mittels Klassenvorhersage
KR20080031038A (ko) * 2005-07-29 2008-04-07 4에스체 악티엔게젤샤프트 신규의 헤테로환 ＮＦ-κＢ 억제제
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
RU2443706C2 (ru) * 2006-04-26 2012-02-27 Дженентек, Инк. Фармацевтические соединения
WO2008064244A2 (en) * 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP1953163A1 (de) * 2007-02-01 2008-08-06 Boehringer Ingelheim Pharma GmbH & Co. KG Pteridinon-Derivate als PI3-Kinases Inhibitoren
WO2008148023A2 (en) * 2007-05-23 2008-12-04 Medical College Of Georgia Research Institute, Inc. Compositions and methods for treating neurological disorders
US20100204222A1 (en) * 2007-09-17 2010-08-12 GlaxoSmithKline, LLC Pyridopyrimidine derivatives as p13 kinase inhibitors
CA2700200A1 (en) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
WO2009091550A2 (en) * 2008-01-14 2009-07-23 Bayer Healthcare Llc Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
WO2009111547A1 (en) * 2008-03-04 2009-09-11 Wyeth 7h-pyrrolo[2,3-h]quinazoline compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
US20110105457A1 (en) * 2008-04-18 2011-05-05 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on pi3k
WO2009155527A2 (en) * 2008-06-19 2009-12-23 Progenics Pharmaceuticals, Inc. Phosphatidylinositol 3 kinase inhibitors
EP2168582A1 (de) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Kombinationen aus substituierten 2,3-dihydroimidazo[1,2-c]chinazolinen
EP2168583A1 (de) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Verwendungen von substituierten 2,3-Dihydroimidazo[1,2-c]quinazolinen zur Behandlung von Myelom
ES2614130T3 (es) * 2008-09-30 2017-05-29 Pfizer Inc. Compuestos de imidazo[1,5]naftiridina, su uso farmacéutico y composiciones
CA2743257C (en) * 2008-11-11 2014-02-11 Myung-Hwa Kim Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
WO2010111432A1 (en) 2009-03-24 2010-09-30 Calistoga Pharmaceuticals Inc. Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
AU2010239312A1 (en) 2009-04-20 2011-11-10 Gilead Calistoga Llc Methods of treatment for solid tumors
DK2899191T3 (da) * 2009-04-30 2017-11-13 Glaxo Group Ltd Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
AU2010292198A1 (en) * 2009-09-09 2012-04-05 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
US20130184270A1 (en) * 2010-04-16 2013-07-18 Bayer Intellectual Property Gmbh Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013538840A (ja) 2010-10-01 2013-10-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−（２−アリールアミノ）アリールスルホンアミドを含有する組み合わせ
ES2639402T3 (es) * 2010-11-11 2017-10-26 Bayer Intellectual Property Gmbh 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol
WO2012062745A1 (en) * 2010-11-11 2012-05-18 Bayer Pharma Aktiengesellschaft Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (de) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituierte 2,3-Dihydroimidazo[1,2-c]chinazolinsalze
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CA2864305C (en) 2012-03-05 2021-02-16 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
KR20150130451A (ko) 2013-03-15 2015-11-23 제넨테크, 인크. 암 치료 방법 및 항암제 내성 예방을 위한 방법
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
CN105263497B (zh) 2013-04-08 2019-04-30 拜耳制药股份公司 取代的2,3-二氢咪唑并[1,2-c]喹唑啉治疗淋巴瘤的用途
AR096151A1 (es) 2013-05-01 2015-12-09 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
EP3083630B1 (de) 2013-12-20 2019-08-21 Gilead Calistoga LLC Prozessverfahren für phosphatidylinositol-3-kinase-hemmer
EP3083623A1 (de) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphe formen eines hydrochloridsalzes aus (s)-2-(9h-purin-6-ylamino)propyl)-5-fluor-3-phenylchinazolin-4 (3h)-on
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3018127A1 (de) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthese von Copanlisib sowie dessen Dihydrochloridsalz
EP3018131A1 (de) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthese von Copanlisib sowie dessen Dihydrochloridsalz
MX2017011635A (es) 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
CN105130997B (zh) * 2015-09-25 2017-12-05 苏州明锐医药科技有限公司 一种库潘尼西的制备方法
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
EP3426657B1 (de) * 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]chinazolin-5-yl]pyrimidin-5-carboxamide
EP3219329A1 (de) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Kombinationen von copanlisib
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN110049783A (zh) 2016-12-14 2019-07-23 塔弗达治疗有限公司 Hsp90-靶向缀合物及其制剂
WO2018153980A1 (en) 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (de) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulierungen von copanlisib
ES2950663T3 (es) 2017-09-08 2023-10-11 Bayer Pharma AG Formulaciones de copanlisib
WO2019060611A1 (en) * 2017-09-20 2019-03-28 Abm Therapeutics, Inc. CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
US12000833B2 (en) 2017-11-23 2024-06-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Marker for predicting the sensitivity to PI3K inhibitors
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
WO2020020385A1 (zh) * 2018-07-27 2020-01-30 上海翰森生物医药科技有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109053554B (zh) * 2018-08-01 2020-07-28 江苏八巨药业有限公司 一种使用催化剂合成3-乙酰吡啶的方法
EP3843743A1 (de) 2018-08-28 2021-07-07 Bayer AS Kombination von pi3k-inhibitoren und zielgerichteten thorium-konjugaten
US20210369724A1 (en) 2018-10-16 2021-12-02 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
MX2021004775A (es) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644354A (en) * 1968-09-16 1972-02-22 Sandoz Ag 5-substituted-2 3-dihydroimidazo(1 2-c)quinazolines
US4287341A (en) 1979-11-01 1981-09-01 Pfizer Inc. Alkoxy-substituted-6-chloro-quinazoline-2,4-diones
CN1033644C (zh) * 1993-01-02 1996-12-25 瑞安大药厂股份有限公司 3-取代甲基-2，3-二氢咪唑并[1，2-c]喹唑啉衍生物，其制备与用途
KR100290129B1 (ko) 1994-08-12 2001-05-15 마이클 바마트 옥시퓨린 누클레오시드로 패혈증 또는 염증성 질병을 치료하는 방법
JP4431638B2 (ja) * 1996-01-29 2010-03-17 アメリカ合衆国 ジヒドロピリジン―、ピリジン―、ベンゾピラン―オン―およびトリアゾロキナゾリン誘導体、それらの製造およびそれらのアデノシン受容体アンタゴニストとしての用途
US5932584A (en) * 1997-05-06 1999-08-03 National Science Council Optically active 2,3-dihydroimidazo(1,2-C) quinazoline derivatives, the preparation and antihypertensive use thereof
US6518277B1 (en) 2000-04-25 2003-02-11 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2001083456A1 (fr) * 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Derives d'heteroaryle condenses

Also Published As

Publication number Publication date
KR101059652B1 (ko) 2011-08-25
AR072458A2 (es) 2010-09-01
WO2004029055A1 (en) 2004-04-08
PT1549652E (pt) 2008-12-15
CN100384846C (zh) 2008-04-30
PE20050089A1 (es) 2005-04-20
MXPA05001808A (es) 2005-08-16
BR0314830A (pt) 2005-08-16
SI2042504T1 (sl) 2011-10-28
AR041426A1 (es) 2005-05-18
US20090270388A1 (en) 2009-10-29
SI1549652T1 (sl) 2009-04-30
PL375935A1 (en) 2005-12-12
DK2042504T3 (da) 2011-09-19
RU2326881C9 (ru) 2009-04-10
KR20050067404A (ko) 2005-07-01
ES2367141T3 (es) 2011-10-28
HRP20050375A2 (en) 2006-05-31
US8129386B2 (en) 2012-03-06
HRP20131159A2 (hr) 2014-05-23
TW200413379A (en) 2004-08-01
RU2005113165A (ru) 2005-10-10
IL166855A (en) 2014-05-28
EP2042504A1 (de) 2009-04-01
JP4790266B2 (ja) 2011-10-12
ATE411996T1 (de) 2008-11-15
ATE511510T1 (de) 2011-06-15
ECSP055768A (es) 2005-08-11
CY1109790T1 (el) 2014-09-10
HRP20050375B1 (hr) 2014-03-14
JP2006508063A (ja) 2006-03-09
UA82205C2 (en) 2008-03-25
CA2499134A1 (en) 2004-04-08
HK1084393A1 (en) 2006-07-28
CA2499134C (en) 2011-12-20
RU2326881C2 (ru) 2008-06-20
BRPI0314830B8 (pt) 2021-05-25
AU2003293310B2 (en) 2010-04-01
DK1549652T3 (da) 2009-02-23
US20060128732A1 (en) 2006-06-15
PT2042504E (pt) 2011-09-07
BRPI0314830B1 (pt) 2018-03-27
AU2003293310A1 (en) 2004-04-19
HRP20131159B1 (hr) 2019-11-01
MY140756A (en) 2010-01-15
US7511041B2 (en) 2009-03-31
MA27483A1 (fr) 2005-08-01
CY1112174T1 (el) 2015-12-09
NO331457B1 (no) 2012-01-09
EP1549652A1 (de) 2005-07-06
EP1549652B1 (de) 2008-10-22
ES2312843T3 (es) 2009-03-01
PL226562B1 (pl) 2017-08-31
NZ539062A (en) 2007-05-31
EP2042504B1 (de) 2011-06-01
ECSP11005768A (es) 2011-03-31
NO20052076L (no) 2005-04-27
TWI327570B (en) 2010-07-21
CN1688582A (zh) 2005-10-26
ZA200503306B (en) 2006-07-26
UY28001A1 (es) 2004-04-30

Similar Documents

Publication Publication Date Title
ATE511510T1 (de) Kondensierte azol-pyrimidin-derivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
DE60330372D1 (de) Indol-3-schwefelderivate
ATE467631T1 (de) Chinuclidinamidderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
ATE438644T1 (de) Chinazolinderivate
DK2248807T3 (da) N-Phenyl-2-pyrimidinaminderivater
ATE318817T1 (de) Aza-arylpiperazine
NO20044046L (no) Substituerte hydroksyetylaminer
DE50311918D1 (de) Nockenwellenversteller
DE50302271D1 (de) Kondensor
ATE349458T1 (de) Etonogestrelester
FI20020700A0 (fi) Sähkösuodatinrakenne
DE60307512D1 (de) 3h-chinazoline -4-on derivaten
ATE423771T1 (de) Tetrahydrochinolinderivate
ATE496887T1 (de) Substituierte 5-aminomethyl-1h-pyrrol-2-carbons ureamide
ATA1572002A (de) Managementspleisskassette
ATE457299T1 (de) 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
ATA4142004A (de) Trägerverbau
ATA19152002A (de) Hubkupplung
DE50310701D1 (de) Magnetfuehrungseinrichtung
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls
DE50306228D1 (de) Substituierte benzdioxepine

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE

8364 No opposition during term of opposition